SCHEMBL19100505

SCHEMBL19100505

Fc1nn(-c2nc(Cl)ncc2C(F)(F)F)c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA5 O75582 4/20 0.39
▸ MAPT P10636 2/20 0.39
▸ RORC P51449 4/20 0.35
▸ HCRTR2 O43614 1/20 0.34
▸ MKNK2 Q9HBH9 2/20 0.34
▸ RPS6KA4 O75676 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CYP11B2 P19099 1/20 0.32
▸ ULK1 O75385 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ XPO1 O14980 1/20 0.31
▸ MKNK1 Q9BUB5 1/20 0.31
▸ RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19100430 0.87 CYP11B2 (0.44) RPS6KA5MAPTRORCHCRTR2RPS6KA4
SCHEMBL19100675 0.86 TTK (0.40) RPS6KA5MAPTRORCHCRTR2MKNK2
SCHEMBL19100496 0.84 RPS6KA5 (0.44) RPS6KA5MAPTRORCMKNK2RPS6KA4
SCHEMBL28600611 0.79 MAPT (0.40) RPS6KA5MAPTRORCHCRTR2MKNK2
SCHEMBL19100325 0.79 PIN1 (0.41) RPS6KA5MAPTMKNK2RPS6KA4SMN1; SMN2
SCHEMBL28605995 0.78 RPS6KA5 (0.42) RPS6KA5MAPTRORCHCRTR2MKNK2
SCHEMBL19100490 0.77 RPS6KA5 (0.39) RPS6KA5MAPTHCRTR2MKNK2RPS6KA4
SCHEMBL19100706 0.76 CYP11B2 (0.32) MAPTRORCHCRTR2CYP11B2CYP2C9
SCHEMBL19100636 0.75 CYP11B2 (0.44) RPS6KA5MAPTRORCMKNK2RPS6KA4
SCHEMBL28605643 0.74 RECQL (0.39) RPS6KA5MAPTRORCHCRTR2MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3399968-B1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LTD (KY) 2021-10-20 — — EP disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed
EP-3399968-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmatech Limited (KY) 2018-11-14 — — EP disclosed
WO-2017120429-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS Pharmasciences, Inc. (US) 2017-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 RPS6KA5 582/4885MAPT 2895/4885RORC 2254/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 RPS6KA5 582/4885MAPT 2895/4885RORC 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback